Current Atherosclerosis Reports最新文献_第2页

Insight into the Mechanistic role of Colchicine in Atherosclerosis. 秋水仙碱在动脉粥样硬化中的作用机制。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-03-20 DOI: 10.1007/s11883-025-01291-1

Hayder M Al-Kuraishy, Ghassan M Sulaiman, Hamdoon A Mohammed, Retaj A Dawood, Ali K Albuhadily, Ali I Al-Gareeb, Daniel J Klionsky, Mosleh M Abomughaid

{"title":"Insight into the Mechanistic role of Colchicine in Atherosclerosis.","authors":"Hayder M Al-Kuraishy, Ghassan M Sulaiman, Hamdoon A Mohammed, Retaj A Dawood, Ali K Albuhadily, Ali I Al-Gareeb, Daniel J Klionsky, Mosleh M Abomughaid","doi":"10.1007/s11883-025-01291-1","DOIUrl":"https://doi.org/10.1007/s11883-025-01291-1","url":null,"abstract":"Purpose of review: Globally, the prevalence of atherosclerosis (AS) is rising. Currently, there is no specific drug for AS. Therefore, this review aims to discuss the protective mechanisms of colchicine against the development and progression of atherosclerosis (AS).Recent findings: Many studies highlighted that the anti-inflammatory drug colchicine reduces the severity of AS, although the underlying mechanism for the beneficial effect of colchicine was not fully clarified. AS is a chronic progressive vascular disorder characterized by the formation of atherosclerotic plaques. Endothelial dysfunction is an initial stage in the pathogenesis of AS that is induced by oxidized low-density lipoprotein (oxLDL). Engulfment of oxLDL by macrophages triggers the development of inflammation due to the release of pro-inflammatory cytokines and growth factors. Inflammatory and adhesion molecules are involved in the pathogenesis of AS. Infiltration and accumulation of leukocytes provoke erosion, rupture, and thrombosis of the atherosclerotic plaque. Therefore, targeting inflammation and leukocyte infiltration by anti-inflammatory agents may reduce AS progression and complications. The anti-inflammatory drug colchicine reduces the severity of AS, although the underlying mechanism for the beneficial effect of colchicine was not fully elucidated.In conclusion: colchicine through inhibition of vascular inflammation, oxidative stress, platelet aggregation and the modulation of autophagy reduces the development and progression of AS.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"40"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room? 选择性过氧化物酶体增殖物激活受体(PPAR)-α调节剂和贝特类药物对微血管疾病的影响：还有空间吗？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-03-20 DOI: 10.1007/s11883-025-01292-0

Lucas Lage Marinho, Matheus Laterza Ribeiro, Patrick R Lawler, Iulia Iatan, Lucas Colombo Godoy, Fabiana Hanna Rached, Raul Cavalcante Maranhão

{"title":"Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?","authors":"Lucas Lage Marinho, Matheus Laterza Ribeiro, Patrick R Lawler, Iulia Iatan, Lucas Colombo Godoy, Fabiana Hanna Rached, Raul Cavalcante Maranhão","doi":"10.1007/s11883-025-01292-0","DOIUrl":"https://doi.org/10.1007/s11883-025-01292-0","url":null,"abstract":"Purpose of review: This review examines the role of fibrates and the selective PPAR-alpha modulators (SPPARM-α), pemafibrate, in diabetic microvascular disease. It reviews their potential to mitigate residual risk in retinopathy, nephropathy, neuropathy and peripheral vascular disease.Recent findings: These pharmacotherapies, beyond their lipid-lowering effects, may exert anti-inflammatory, antioxidant, and endothelial-protective actions. Secondary analyses of large clinical trials supports their efficacy in slowing retinopathy progression, reducing albuminuria, and preventing minor amputations. Recent analyses suggest that pemafibrate offers an enhanced efficacy and safety profile compared to conventional fibrate and may lower the incidence of diabetic foot ulcers and gangrene. Fibrates and SPPARM-α agonists represent promising therapies to prevent diabetic microvascular complications. Their benefits in reducing microvascular damage support their broader adoption in clinical practice. However, additional dedicated randomized trials are essential to validate the efficacy of those agents in contemporary diabetes care era and to address the growing burden of diabetes-related microvascular complications.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"39"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Sex Differences on Lipids and Statin Utilization. 性别差异对血脂和他汀类药物使用的影响。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-03-18 DOI: 10.1007/s11883-025-01286-y

Carla P Rodriguez, Semenawit Burka, Erin D Michos

{"title":"Impact of Sex Differences on Lipids and Statin Utilization.","authors":"Carla P Rodriguez, Semenawit Burka, Erin D Michos","doi":"10.1007/s11883-025-01286-y","DOIUrl":"https://doi.org/10.1007/s11883-025-01286-y","url":null,"abstract":"Purpose of the review: Hypercholesterolemia is a significant and modifiable risk factor for cardiovascular disease (CVD), with Low-Density Lipoprotein Cholesterol (LDL-C) being the primary target for lipid-lowering therapies in both primary and secondary prevention. This review aims to explore the efficacy of statin therapy in women, its safety and application during pregnancy, and treatment disparities that contribute to undertreatment of dyslipidemia in women.Recent findings: Statins has demonstrated efficacy in reducing LDL-C and CVD risk in women. However, women are less likely to achieve LDL-C targets compared to men, largely due to undertreatment and delays in initiating therapy, often influenced by sex-specific factors. The unique considerations of lipid management during pregnancy, including suspension of statin therapy, present additional challenges in achieving optimal lipid control in high-risk women. Evidence also points to systemic disparities in healthcare delivery and treatment allocation, further exacerbating undertreatment of dyslipidemia among women. While LDL-C lowering remains a cornerstone of CVD prevention, women face distinct challenges in achieving lipid goals due to biological, clinical, and healthcare disparities. Addressing these barriers, including improving timely initiation of statins and addressing gaps in care during pregnancy, is essential to enhance the dyslipidemia management and reduce CVD risk in women.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"38"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond Cholesterol: Unraveling Residual Lipidomic Risk in Cardiovascular Health. 超越胆固醇：揭示残留脂质组学在心血管健康中的风险。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-03-17 DOI: 10.1007/s11883-025-01284-0

Matthew K Campbell, Nicholas W S Chew, Anurag Mehta

{"title":"Beyond Cholesterol: Unraveling Residual Lipidomic Risk in Cardiovascular Health.","authors":"Matthew K Campbell, Nicholas W S Chew, Anurag Mehta","doi":"10.1007/s11883-025-01284-0","DOIUrl":"https://doi.org/10.1007/s11883-025-01284-0","url":null,"abstract":"Purpose of review: This paper reviews the existing literature on lipidomics as a tool for improved cardiovascular risk estimation in both primary and secondary prevention populations.Recent findings: Detailed lipidomic signatures identified by mass spectrometry have been shown to enhance risk estimation for clinical CAD and the presence of subclinical CAD on CTCA in multiple large cohort populations. In patients with established atherosclerotic disease, ceramide and phospholipid-based risk scores improve prediction for recurrent cardiovascular events and cardiovascular death. Lipidomic profiles and lipidomic-enhanced risk scores have been shown to improve prediction of incident cardiovascular disease, recurrent cardiovascular events and cardiovascular death independent of traditional risk factors. Simplified risk scores utilizing the ratios of several ceramide species improve clinical utility, however resources and infrastructure limit widespread implementation. There are currently no therapeutics to address lipidomic risk aside from traditional risk factor modification.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"37"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Built Environment and Cardiovascular Diseases - Insights from a Global Review. 建筑环境与心血管疾病——来自全球综述的见解。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-03-05 DOI: 10.1007/s11883-025-01282-2

Ali Aahil Noorali, Asma Altaf Hussain Merchant, Noreen Afzal, Rupshikha Sen, Vashma Junaid, Adeel Khoja, Sadeer Al-Kindi, Elizabeth M Vaughan, Unab I Khan, Nilofer F Safdar, Salim S Virani, Sana Sheikh

{"title":"Built Environment and Cardiovascular Diseases - Insights from a Global Review.","authors":"Ali Aahil Noorali, Asma Altaf Hussain Merchant, Noreen Afzal, Rupshikha Sen, Vashma Junaid, Adeel Khoja, Sadeer Al-Kindi, Elizabeth M Vaughan, Unab I Khan, Nilofer F Safdar, Salim S Virani, Sana Sheikh","doi":"10.1007/s11883-025-01282-2","DOIUrl":"10.1007/s11883-025-01282-2","url":null,"abstract":"Purpose of review: This narrative review aims to synthesize global literature on the relationship between cardiovascular diseases (CVD) and components of built environment (green spaces, walkability, food environment, accessibility and availability of recreational and healthcare facilities, and effects of air and noise pollution).Recent findings: Increased green space and neighborhood walkability are associated with lower CVD mortality and morbidity; however, benefits have shown differential effects by socioeconomic status (SES). Air pollution is a leading environmental risk factor contributing to CVDs, and it disproportionately impacts low SES populations and women. Findings on relationships between food environment and CVDs are inconsistent and limited. This global review reports on the multifactorial and complex relationship between built environment and higher CVD risk and poor CVD outcomes. Future research can address an unmet need to understand this relationship with further depth and breadth, and to investigate resulting health disparities.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"36"},"PeriodicalIF":5.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport? AEGIS后的现状：靶向逆转胆固醇转运的新治疗机会？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-02-26 DOI: 10.1007/s11883-025-01281-3

Nick S R Lan, Gerald F Watts

{"title":"Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?","authors":"Nick S R Lan, Gerald F Watts","doi":"10.1007/s11883-025-01281-3","DOIUrl":"10.1007/s11883-025-01281-3","url":null,"abstract":"Purpose of review: High-density lipoprotein (HDL) is integral to reverse cholesterol transport (RCT), a process considered to protect against atherosclerotic cardiovascular disease (ASCVD). We summarise findings from the recent AEGIS-II trial and discuss new opportunities for HDL therapeutics targeted at RCT.Recent findings: Mendelian randomisation studies have suggested a causal association between the functional properties of HDL and ASCVD. However, the AEGIS-II trial of CSL112, an apolipoprotein A-I therapy that enhances cholesterol efflux, did not meet its primary endpoint. Exploratory analyses demonstrated that CSL112 significantly reduced ASCVD events among participants with a baseline low-density lipoprotein (LDL)-cholesterol ≥ 100 mg/dL, suggesting that RCT may depend on LDL-cholesterol levels. The role of HDL therapeutics in patients with familial hypercholesterolaemia, inherited low HDL-cholesterol and impaired HDL function, especially with inadequately controlled LDL-cholesterol, merits further investigation. The treatment of patients with monogenic defects in HDL metabolism remains a significant gap in care that needs further research.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"35"},"PeriodicalIF":5.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Striving Towards Equity in Cardiovascular Genomics Research. 努力实现心血管基因组学研究的公平性。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-02-18 DOI: 10.1007/s11883-025-01277-z

Javier Jurado Vélez, Nekayla Anderson, Ivree Datcher, Christy Foster, Pamela Jackson, Bertha Hidalgo

{"title":"Striving Towards Equity in Cardiovascular Genomics Research.","authors":"Javier Jurado Vélez, Nekayla Anderson, Ivree Datcher, Christy Foster, Pamela Jackson, Bertha Hidalgo","doi":"10.1007/s11883-025-01277-z","DOIUrl":"10.1007/s11883-025-01277-z","url":null,"abstract":"Purpose of review: Our review emphasizes recent advancements and persisting gaps in cardiovascular genomics, particularly highlighting how emerging studies involving underrepresented populations have uncovered new genetic variants associated with cardiovascular diseases.Recent findings: Initiatives like the H3Africa project, the Million Veterans Program, and the All of Us Research Program are working to address this gap by focusing on underrepresented groups. Additionally, emerging research is centering on the interplay between genetic factors and socio-environmental determinants of health, which disproportionately impact marginalized communities. As cardiovascular genomics research grows, increasing the inclusion of underrepresented populations is essential for gaining a more comprehensive understanding of genetic variability. This will lead to more accurate and clinically meaningful strategies for preventing and treating cardiovascular diseases across all ancestral backgrounds and diverse populations.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"34"},"PeriodicalIF":5.7,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-based Differences in Complications Following Percutaneous Coronary Interventions. 经皮冠状动脉介入术后并发症的性别差异

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-02-17 DOI: 10.1007/s11883-025-01278-y

Mirvat Alasnag, Giulia Masiero, Sinjini Biswas, Ing Haan

{"title":"Sex-based Differences in Complications Following Percutaneous Coronary Interventions.","authors":"Mirvat Alasnag, Giulia Masiero, Sinjini Biswas, Ing Haan","doi":"10.1007/s11883-025-01278-y","DOIUrl":"https://doi.org/10.1007/s11883-025-01278-y","url":null,"abstract":"Purpose of review: The role that sex plays in the incidence and outcomes of PCI related complications is not well understood. The purpose of this review is to highlight the commonly encountered peri-procedural complications and search for any sex differences in the published literature.Recent findings: Procedure related complications and long-term cardiovascular outcomes remain worse in women. The delayed presentation of women with coronary events and delayed referral for an invasive diagnostic angiogram and subsequent revascularization likely contribute to the worse outcomes. Whether the smaller vessel size, residual Syntax Score, and other biological factors impact periprocedural outcomes is controversial and warrants device and procedure specific research to identify sex differences. Modern day percutaneous revascularization has achieved very high acute procedural success rates and low complication rates with the advent of structured training programs, development of appropriate use criteria and refined devices and technologies in the catheterization laboratory. However, both procedure related complications and long-term cardiovascular outcomes remain worse in women.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"33"},"PeriodicalIF":5.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy. 通过非他汀类降脂治疗实现更优的脂质控制。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-02-15 DOI: 10.1007/s11883-025-01280-4

Stephen J Nicholls, Adam J Nelson

{"title":"Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy.","authors":"Stephen J Nicholls, Adam J Nelson","doi":"10.1007/s11883-025-01280-4","DOIUrl":"10.1007/s11883-025-01280-4","url":null,"abstract":"Purpose of review: The use of statins has transformed approaches to the prevention of cardiovascular disease. However, many patients remain at a major risk of experiencing cardiovascular events, due to a range of factors including suboptimal control of low-density lipoprotein cholesterol (LDL-C). Accordingly, there is an ongoing need to develop additional strategies, beyond the use of statins, to achieve more effective reductions in cardiovascular risk.Recent findings: Genomic studies have implicated the causal role of LDL in atherosclerosis and identified that polymorphisms influencing factors involved in lipid metabolism influence both the level of LDL-C and cardiovascular risk. These findings have highlighted the potential for cardiovascular benefit from development of therapies targeting these factors and incremental benefit when used in combination with statins. Clinical trials have demonstrated that these new agents have favourable effects on both atherosclerotic plaque and cardiovascular events. Additional work has sought to improve intensification of statin therapy and adherence with lipid lowering therapy, to achieve more effective cardiovascular prevention via lipid lowering. Emerging therapies, beyond statins, have the potential to optimise lipid levels and play an effective role in the prevention of cardiovascular disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"32"},"PeriodicalIF":5.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging Mobile Health and Wearable Technologies for the Prevention and Management of Atherosclerotic Cardiovascular Disease. 利用移动医疗和可穿戴技术预防和管理动脉粥样硬化性心血管疾病。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-02-11 DOI: 10.1007/s11883-024-01272-w

Pouria Alipour, Mawada El-Aghil, Ariel Foo, Zahra Azizi

{"title":"Leveraging Mobile Health and Wearable Technologies for the Prevention and Management of Atherosclerotic Cardiovascular Disease.","authors":"Pouria Alipour, Mawada El-Aghil, Ariel Foo, Zahra Azizi","doi":"10.1007/s11883-024-01272-w","DOIUrl":"https://doi.org/10.1007/s11883-024-01272-w","url":null,"abstract":"Purpose of review: This review aims to assess the role of mobile health (mHealth) interventions and wearable technologies in the prevention and management of atherosclerotic cardiovascular disease (ASCVD). We sought to explore the benefits, challenges, and equity implications of these digital health modalities, with a focus on improving patient outcomes and reducing ASCVD risk.Recent findings: Recent studies have shown that mHealth interventions and wearable devices effectively promote healthy behaviors, offer real-time physiological monitoring, and aid in the early prevention of ASCVD by targeting key risk factors such as metabolic syndrome and sedentary lifestyles. These technologies hold great potential for improving patient engagement and enabling timely interventions. However, challenges such as technological constraints, high costs, and gaps in digital literacy significantly hinder their broader adoption, particularly among disadvantaged populations. In summary, our findings highlight the critical need for accessible, affordable, and inclusive digital health solutions to prevent and manage ASCVD, promoting more equitable healthcare delivery. To maximize these benefits, future research should focus on harnessing artificial intelligence and digital markers to improve early event prediction and develop personalized preventive strategies.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"31"},"PeriodicalIF":5.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0